# EDGAR Filing Document

**Accession Number:** 0001739174
**File Stem:** 0001213900-26-027698
**Filing Date:** 2026-3
**Character Count:** 7282
**Document Hash:** efd6cfeadbfda78f99051c925641bf99
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-027698.hdr.sgml**: 20260313

**ACCESSION NUMBER**: 0001213900-26-027698

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260311

**FILED AS OF DATE**: 20260313

**DATE AS OF CHANGE**: 20260313

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Yeganeh Reuven
- **CENTRAL INDEX KEY:** 0002044677

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38762
- **FILM NUMBER:** 26752893

**MAIL ADDRESS:**
- **STREET 1:** HASIRIM 48
- **CITY:** GIRAT SHEMYEL
- **STATE:** L3
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BiomX Inc.
- **CENTRAL INDEX KEY:** 0001739174
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823364020
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 850 NEW BURTON ROAD
- **STREET 2:** SUITE 201
- **CITY:** DOVER
- **STATE:** DE
- **ZIP:** 19904
- **BUSINESS PHONE:** 972 545610935

**MAIL ADDRESS:**
- **STREET 1:** 850 NEW BURTON ROAD
- **STREET 2:** SUITE 201
- **CITY:** DOVER
- **STATE:** DE
- **ZIP:** 19904

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chardan Healthcare Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180430

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Yeganeh Reuven<br><sub>(Last) (First) (Middle)</sub><br>C/O BIOMX INC.<br>22 EINSTEIN ST., FLOOR 4<br><sub>(Street)</sub><br>NESS ZIONA, IL 414003<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BiomX Inc. [ PHGE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock, $0.0001 par value per share | 2026-03-11 |  | C<sup>(1)</sup> |  | 300000 | A | 2.00<sup>(1)</sup> | 30000 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |
| Common Stock, $0.0001 par value per share | 2026-03-12 |  | S<sup>(3)</sup> |  | 300000 | D | 5.00<sup>(3)</sup> | 0 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |
| Common Stock, $0.0001 par value per share | 2026-03-13 |  | C<sup>(1)</sup> |  | 370000 | A | 2.00<sup>(1)</sup> | 370000 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |
| Common Stock, $0.0001 par value per share | 2026-03-13 |  | S<sup>(3)</sup> |  | 370000 | D | 5.00<sup>(3)</sup> | 0 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series Y Convertible Preferred Stock | 2.00<sup>(1)</sup> | 2026-03-12 |  | C<sup>(1)</sup> |  |  | 600 | 2026-01-13 | 2027-01-13 | Common Stock | 300000 | 0<sup>(1)</sup> | 2700 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |
| Series Y Convertible Preferred Stock | 2.00<sup>(1)</sup> | 2026-03-13 |  | C<sup>(1)</sup> |  |  | 740 | 2026-01-13 | 2027-01-13 | Common Stock | 370000 | 0<sup>(1)</sup> | 1960 | I | Pyu Pyu Capital LLC<sup>(2)</sup> |

---

### Footnotes:

(1) Represents shares of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer received upon conversion of the Issuer's Series Y Convertible Preferred Stock, par value $0.0001 per share, held by the Reporting Person at a conversion price equal to $2.00 per share.

(2) The reported securities are directly owned by Pyu Pyu Capital, LLC ("Pyu Pyu") and may be deemed to be beneficially owned by the Reporting Person as sole member of Pyu Pyu. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

(3) The shares of Common Stock were sold in private transactions at a price of $5.00 per share.

**Signature:** /s/ Reuven Yeganeh  
**Date:** 2026-03-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**